1M.B. Ch. B, DOG, CABOG, FIBMS OG, College of Medicine, University of Babylon, Hilla, Iraq
2Professor and Consultant Obstetrician and Gynecologist, Obstetrics and gynecology Department, College of Medicine, Kufa University, Kufa, Iraq
3Assist. Professor in Department Of Applied Embryology, High Institute of Infertility Diagnosis and ART, AL Nahrain University, Baghdad, Iraq
*Corresponding author: Nassrin Malik Aubead Email: nassrinmalik1@yahoo.com, maliknassrin@yahoo.com
Online published on 26 September, 2019.
The Objective of this study is to compare the results of luteal phase treatment by estradiol versus GnRH antagonist on antral follicular size coordination and hormonal levels before ICSI cycles, assessment of follicular growth synchronization during controlled ovarian stimulation and evaluate ICSI outcome. This a prospective randomized clinical trial included 60 infertile women evaluated in second day of menstrual cycle for antral count and their sizes, FSH, LH, estradiol, and progesterone, then assigned randomly according to luteal treatment to 3 groups; with 20 patients in each treated with estradiol, or cetrorelix acetate or no treatment. All then enrolled in ICSI with flexible antagonist protocol. Findings revealed significantly reduction of antral follicles sizes, and improve their growth symmetry in early follicular phase after treatment, reduction in second day FSH, LH and progesterone. Reduction in follicular growth discrepancies at day 8. At trigger day the antagonist group had a significant more numbers of the follicles size ≥17 mm. larger number of retrieved-oocytes, (MII) than other groups, (P<0.05). No significant difference in biochemical and clinical pregnancy rates between groups. In conclusions premenstrual estradiol or GnRH antagonist treatment decrease size discrepancies of antral follicles, and improve synchronization of their growth.
ICSI, synchronization, GnRH antagonist, estradiol
